David P. Southwell Buys 25,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

TScan Therapeutics, Inc. (NASDAQ:TCRXGet Rating) CEO David P. Southwell bought 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The shares were bought at an average price of $3.59 per share, with a total value of $89,750.00. Following the transaction, the chief executive officer now owns 171,569 shares of the company’s stock, valued at approximately $615,932.71. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ:TCRX traded up $0.05 during trading hours on Friday, hitting $3.05. 40,565 shares of the company’s stock traded hands, compared to its average volume of 88,598. The business has a fifty day moving average price of $2.69 and a 200-day moving average price of $4.67. TScan Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $14.71.

Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of TScan Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 13th. HC Wainwright decreased their price target on shares of TScan Therapeutics from $21.00 to $15.00 in a research note on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, TScan Therapeutics has an average rating of “Buy” and a consensus price target of $16.35.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Caas Capital Management LP purchased a new position in TScan Therapeutics during the 3rd quarter worth $626,000. Schonfeld Strategic Advisors LLC purchased a new position in TScan Therapeutics in the 3rd quarter worth $185,000. Wellington Management Group LLP acquired a new stake in TScan Therapeutics during the 3rd quarter valued at approximately $1,163,000. DC Investments Management LLC purchased a new stake in shares of TScan Therapeutics in the third quarter worth about $297,000. Finally, DC Funds LP purchased a new position in shares of TScan Therapeutics during the 3rd quarter valued at approximately $5,254,000. Institutional investors own 36.97% of the company’s stock.

TScan Therapeutics Company Profile (Get Rating)

TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.

Further Reading

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.